Post-mortem investigations showed BCMA expression on neurons and astrocytes in the basal ganglia of a patient, indicating a rare, on-target off-tumor toxicity effect of the anti-BCMA CAR-T cell therapy.4 However, further investigations are needed to confirm the BCMA expression in the CNS and the possible effects of anti-BCMA CAR-T cells. Here, TNFRSF17 is linked to neoplasm.